Cargando…

CAR T Cell-Based Immunotherapy for the Treatment of Glioblastoma

Glioblastoma multiforme (GBM) is the most common and aggressive malignant primary brain tumor in adults. Current treatment options typically consist of surgery followed by chemotherapy or more frequently radiotherapy, however, median patient survival remains at just over 1 year. Therefore, the need...

Descripción completa

Detalles Bibliográficos
Autores principales:	Maggs, Luke, Cattaneo, Giulia, Dal, Ali Emre, Moghaddam, Ali Sanjari, Ferrone, Soldano
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2021
Materias:	Neuroscience
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8185049/ https://www.ncbi.nlm.nih.gov/pubmed/34113233 http://dx.doi.org/10.3389/fnins.2021.662064

Ejemplares similares

B7-H3-targeted CAR T cell activity is enhanced by radiotherapy in solid cancers
por: Ventin, Marco, et al.
Publicado: (2023)

Stressed target cancer cells drive nongenetic reprogramming of CAR T cells and tumor microenvironment, overcoming multiple obstacles of CAR T therapy for solid tumors
por: Wang, Yufeng, et al.
Publicado: (2023)

Stressed target cancer cells drive nongenetic reprogramming of CAR T cells and solid tumor microenvironment
por: Wang, Yufeng, et al.
Publicado: (2023)

CAR-Engineered NK Cells for the Treatment of Glioblastoma: Turning Innate Effectors Into Precision Tools for Cancer Immunotherapy
por: Burger, Michael C., et al.
Publicado: (2019)

Resistance to anti-PD-1-based immunotherapy in basal cell carcinoma: a case report and review of the literature
por: Sabbatino, Francesco, et al.
Publicado: (2018)

Intratumoral IL-12 delivery empowers CAR-T cell immunotherapy in a pre-clinical model of glioblastoma
por: Agliardi, Giulia, et al.
Publicado: (2021)

Canine Melanoma Immunology and Immunotherapy: Relevance of Translational Research
por: Tarone, Lidia, et al.
Publicado: (2022)

Nanobody-based CAR-T cells for cancer immunotherapy
por: Safarzadeh Kozani, Pouya, et al.
Publicado: (2022)

New cell sources for CAR-based immunotherapy
por: Mazinani, Marzieh, et al.
Publicado: (2023)

GD2 CAR T cells against human glioblastoma
por: Prapa, Malvina, et al.
Publicado: (2021)

The Molecular and Microenvironmental Landscape of Glioblastomas: Implications for the Novel Treatment Choices
por: Di Cintio, Federica, et al.
Publicado: (2020)

Application of blood brain barrier models in pre-clinical assessment of glioblastoma-targeting CAR-T based immunotherapies
por: Huang, Jez, et al.
Publicado: (2022)

CAR-neutrophil mediated delivery of tumor-microenvironment responsive nanodrugs for glioblastoma chemo-immunotherapy
por: Chang, Yun, et al.
Publicado: (2023)

Dendritic Cell-Based Immunotherapy Treatment for Glioblastoma Multiforme
por: Yang, Liu, et al.
Publicado: (2015)

Allogeneic CAR T Cells: An Alternative to Overcome Challenges of CAR T Cell Therapy in Glioblastoma
por: Martínez Bedoya, Darel, et al.
Publicado: (2021)

Chondroitin sulfate proteoglycan 4 expression in chondrosarcoma: A potential target for antibody-based immunotherapy
por: Nota, Sjoerd P. F. T., et al.
Publicado: (2022)

Adoptive Immunotherapy beyond CAR T-Cells
por: Titov, Aleksei, et al.
Publicado: (2021)

Versatile CAR T-cells for cancer immunotherapy
por: Chu, Fuliang, et al.
Publicado: (2018)

Tuning the performance of CAR T cell immunotherapies
por: Richardson, Noah H., et al.
Publicado: (2019)

Immunotherapy Deriving from CAR-T Cell Treatment in Autoimmune Diseases
por: Chen, Yuehong, et al.
Publicado: (2019)

CAR race to cancer immunotherapy: from CAR T, CAR NK to CAR macrophage therapy
por: Pan, Kevin, et al.
Publicado: (2022)

NK Cell-Based Glioblastoma Immunotherapy
por: Golán, Irene, et al.
Publicado: (2018)

Cell-based immunotherapy of glioblastoma multiforme
por: Bryukhovetskiy, Igor
Publicado: (2022)

Gene Targets of CAR-T Cell Therapy for Glioblastoma
por: Wang, Chaoqun, et al.
Publicado: (2023)

Sex Differences are Reflected in Microstructural White Matter Alterations of Musical Sophistication: A Diffusion MRI Study
por: Mehrabinejad, Mohammad-Mehdi, et al.
Publicado: (2021)

CAR-NK Cell: A New Paradigm in Tumor Immunotherapy
por: Marofi, Faroogh, et al.
Publicado: (2021)

Advances in immunotherapy for the treatment of glioblastoma
por: Tivnan, Amanda, et al.
Publicado: (2016)

Biomarkers for immunotherapy for treatment of glioblastoma
por: Lynes, John P, et al.
Publicado: (2020)

CAR‐NK cell in cancer immunotherapy; A promising frontier
por: Marofi, Faroogh, et al.
Publicado: (2021)

Cars, Compositionality, and Consciousness
por: Kaplan, Frederic
Publicado: (2008)

CAR-T Cells Immunotherapies for the Treatment of Acute Myeloid Leukemia—Recent Advances
por: Zarychta, Julia, et al.
Publicado: (2023)

T Cell Exhaustion and CAR-T Immunotherapy in Hematological Malignancies
por: Tang, Lu, et al.
Publicado: (2021)

CAR T Cell Immunotherapy Beyond Haematological Malignancy
por: Hupperetz, Cedric, et al.
Publicado: (2022)

Opportunities for CAR-T Cell Immunotherapy in HIV Cure
por: Campos-Gonzalez, Gerard, et al.
Publicado: (2023)

Association Between Peripheral Inflammation and DATSCAN Data of the Striatal Nuclei in Different Motor Subtypes of Parkinson Disease
por: Sanjari Moghaddam, Hossein, et al.
Publicado: (2018)

Safety profile of chimeric antigen receptor T-cell immunotherapies (CAR-T) in clinical practice
por: Bonaldo, Giulia, et al.
Publicado: (2021)

Overexpression of miR-489 enhances efficacy of 5-fluorouracil-based treatment in breast cancer stem cells by targeting XIAP
por: Wang, Xuedong, et al.
Publicado: (2017)

Virus-Based Immunotherapy of Glioblastoma
por: Martikainen, Miika, et al.
Publicado: (2019)

Prospective approaches to enhancing CAR T cell therapy for glioblastoma
por: Choi, Sun Il, et al.
Publicado: (2022)

Pancreatic cancer: Hurdles in the engineering of CAR-based immunotherapies
por: Abate-Daga, Daniel, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_4cfcqspsh0ur7fmaehjjd3a05r